4596.T
The company operates in the pharmaceuticals industry, primarily generating revenue through the development, production, and sale of prescription drugs and related healthcare products.
Business. The company operates in the pharmaceuticals industry, primarily generating revenue through the development, production, and sale of prescription drugs and related healthcare products.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the pharmaceuticals industry, primarily generating revenue through the development, production, and sale of prescription drugs and related healthcare products.
The company maintains a strong liquidity position, with cash and equivalents amounting to ¥1,918,615,000, which significantly exceeds its total liabilities of ¥165,625,000, resulting in a current ratio of 12.51. This indicates a robust ability to meet short-term obligations. The price-to-book ratio of 4.81 suggests that the market values the company at a premium relative to its book value, which may reflect expectations of future earnings or intangible assets.
Profitability metrics are currently negative, with a return on equity of -0.3728 and a return on assets of -0.3416, indicating that the company is not generating returns for shareholders or effectively utilizing its assets. The operating income and net income are both negative, with operating income at -¥676,983,000 and net income at -¥676,253,000, which is a significant concern for investors. These figures suggest that the company is experiencing operational challenges and may be incurring substantial costs that outweigh its revenues.
The company's revenue is concentrated in a single business segment, as no specific segments are disclosed in the available data. Geographically, the company's exposure is not detailed, but the lack of segment information implies that it may not have a diversified geographic or product portfolio. This concentration could pose a risk if the company's primary market or product line experiences a downturn.
The company's growth trajectory is currently negative, with a significant decline in operating and net income. The outlook for the current fiscal year is not provided, but the negative financial performance suggests a challenging period ahead. The company's capital expenditures are relatively low at -¥10,631,000, which may indicate a focus on cost control rather than expansion. However, the lack of investment in growth initiatives could hinder long-term competitiveness.
Risk factors include the company's negative profitability and the potential for further financial distress. The risk assessment indicates low liquidity and dilution risks, but the negative operating cash flow of -¥583,000,000 is a red flag. The company has not issued any recent dilutive events, and the dilution potential is low, which is a positive aspect. However, the negative financial performance may necessitate future financing, which could lead to dilution if not managed carefully.
Recent events, as reflected in the financial data, show a decline in earnings, with the last actual EPS at -¥10.59 and revenue at ¥21,340,000. These figures indicate a challenging period for the company, with no immediate signs of improvement. The company's financial health is a concern, and investors should monitor future filings and earnings reports for any signs of recovery or further deterioration.
- The company has a strong liquidity position, with a current ratio of 12.51 and significant cash reserves.
- Profitability is negative, with a return on equity of -0.3728 and a return on assets of -0.3416.
- The company's revenue is concentrated in a single segment, and geographic exposure is not detailed.
- Growth is currently negative, with a significant decline in operating and net income.
- The company has low liquidity and dilution risks, but the negative operating cash flow is a concern.
- Recent financial performance indicates a challenging period for the company, with no immediate signs of improvement.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- 4596.T Market data — financials · 2026-05-26
- Kubota Pharmaceutical Holdings Co Ltd Market data — analyst estimates · 2026-05-26